HNB
ACRS icon

Huntington National Bank’s Aclaris Therapeutics ACRS Stock Holding History

Huntington National Bank’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42K Buy
+458
New +$2.04K ﹤0.01% 2417
2024
Q1 		– Sell
-334
Closed -$351 – 3962
2023
Q4 		$351 Buy
+334
New +$1.02K ﹤0.01% 2314

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Huntington National Bank's ACRS Position: Q2 2026 in Review

Huntington National Bank opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 458 shares worth $2.42K. The stake represents ﹤0.01% of the portfolio and ranks #2417 among its holdings. This is a return to the name: Huntington National Bank previously reported a position in ACRS as recently as Q4 2023.

Huntington National Bank first reported a position in ACRS in Q4 2023 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Huntington National Bank held 458 shares of Aclaris Therapeutics worth $2.42K as of Q2 2026.
  • Aclaris Therapeutics was a new Huntington National Bank position in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #2417 holding.
  • Huntington National Bank first reported a position in Aclaris Therapeutics in Q4 2023 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.